Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

2.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
3.

Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.

Wang W, Chen Q, Ford-Siltz LA, Katzelnick LC, Parra GI, Song HS, Vassell R, Weiss CD.

Clin Infect Dis. 2019 May 30;68(12):2067-2078. doi: 10.1093/cid/ciy818.

PMID:
30256912
4.

HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.

Keller PW, Morrison O, Vassell R, Weiss CD.

J Virol. 2018 Jul 31;92(16). pii: e00583-18. doi: 10.1128/JVI.00583-18. Print 2018 Aug 15.

5.

Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.

Meseda CA, Atukorale V, Soto J, Eichelberger MC, Gao J, Wang W, Weiss CD, Weir JP.

Sci Rep. 2018 Mar 29;8(1):5364. doi: 10.1038/s41598-018-23712-9.

6.

Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.

Wang W, Song HS, Keller PW, Alvarado-Facundo E, Vassell R, Weiss CD.

J Virol. 2018 May 29;92(12). pii: e00247-18. doi: 10.1128/JVI.00247-18. Print 2018 Jun 15.

7.

Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic.

Lo CY, Strobl SL, Dunham K, Wang W, Stewart L, Misplon JA, Garcia M, Gao J, Ozawa T, Price GE, Navidad J, Gradus S, Bhattacharyya S, Viboud C, Eichelberger MC, Weiss CD, Gorski J, Epstein SL.

Open Forum Infect Dis. 2017 Feb 12;4(2):ofx023. doi: 10.1093/ofid/ofx023. eCollection 2017 Spring.

8.

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.

Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, Weiss CD, Weir JP.

PLoS One. 2017 Apr 19;12(4):e0175733. doi: 10.1371/journal.pone.0175733. eCollection 2017.

9.

Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.

Alvarado-Facundo E, Vassell R, Schmeisser F, Weir JP, Weiss CD, Wang W.

PLoS One. 2016 Feb 10;11(2):e0149149. doi: 10.1371/journal.pone.0149149. eCollection 2016.

10.

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity.

Wang W, DeFeo CJ, Alvarado-Facundo E, Vassell R, Weiss CD.

J Virol. 2015 Oct;89(20):10602-11. doi: 10.1128/JVI.00939-15. Epub 2015 Aug 12.

11.

Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses.

Wang W, Alvarado-Facundo E, Chen Q, Anderson CM, Scott D, Vassell R, Weiss CD.

J Infect Dis. 2016 Feb 1;213(3):403-6. doi: 10.1093/infdis/jiv407. Epub 2015 Aug 4.

PMID:
26243315
12.

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, Montefiori DC, Barnett SW, Weiss CD.

PLoS One. 2015 Jun 18;10(6):e0128562. doi: 10.1371/journal.pone.0128562. eCollection 2015.

13.

Influenza virus M2 protein ion channel activity helps to maintain pandemic 2009 H1N1 virus hemagglutinin fusion competence during transport to the cell surface.

Alvarado-Facundo E, Gao Y, Ribas-Aparicio RM, Jiménez-Alberto A, Weiss CD, Wang W.

J Virol. 2015 Feb;89(4):1975-85. doi: 10.1128/JVI.03253-14. Epub 2014 Dec 3.

14.

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.

De Feo CJ, Wang W, Hsieh ML, Zhuang M, Vassell R, Weiss CD.

Retrovirology. 2014 Oct 2;11:86. doi: 10.1186/s12977-014-0086-8.

15.

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

De Feo CJ, Weiss CD.

Viruses. 2012 Dec;4(12):3859-911. Review.

16.

Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD.

J Biol Chem. 2012 Mar 9;287(11):8297-309. doi: 10.1074/jbc.M111.324483. Epub 2012 Jan 10.

18.

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2.

Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, Xie H, Ye Z, Scott D, Weiss CD.

PLoS Pathog. 2011 Jun;7(6):e1002081. doi: 10.1371/journal.ppat.1002081. Epub 2011 Jun 9.

19.

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.

Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD.

Virology. 2010 Nov 25;407(2):374-80. doi: 10.1016/j.virol.2010.08.027. Epub 2010 Sep 24.

20.

Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.

Wang W, Xie H, Ye Z, Vassell R, Weiss CD.

J Virol Methods. 2010 May;165(2):305-10. doi: 10.1016/j.jviromet.2010.02.009. Epub 2010 Feb 11.

PMID:
20153374
21.

Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.

Vaccine. 2010 Jan 8;28(3):699-706. doi: 10.1016/j.vaccine.2009.10.078. Epub 2009 Nov 1.

PMID:
19887133
22.

Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.

Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD.

J Virol Methods. 2008 Nov;153(2):111-9. doi: 10.1016/j.jviromet.2008.07.015. Epub 2008 Sep 4.

PMID:
18722473
23.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325
24.

Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD.

J Virol. 2005 Apr;79(8):4774-81.

25.

HIV-1 gp41: mediator of fusion and target for inhibition.

Weiss CD.

AIDS Rev. 2003 Oct-Dec;5(4):214-21. Review.

PMID:
15012000
27.

Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry.

Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomiç M, Weiss CD, Broder CC, Strebel K, Clouse KA.

Blood. 2004 Mar 1;103(5):1586-94. Epub 2003 Oct 30.

28.

Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.

He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD.

J Virol. 2003 Feb;77(3):1666-71.

29.

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.

Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, Gorny MK, Zolla-Pazner S, Dimitrov DS, Weiss CD.

J Virol. 2002 Jul;76(13):6780-90.

31.

Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Weng Y, Yang Z, Weiss CD.

J Virol. 2000 Jun;74(11):5368-72. Erratum in: J Virol 2000 Oct;74(20):9811.

33.

Capture of an early fusion-active conformation of HIV-1 gp41.

Furuta RA, Wild CT, Weng Y, Weiss CD.

Nat Struct Biol. 1998 Apr;5(4):276-9. Erratum in: Nat Struct Biol 1998 Jul;5(7):612.

PMID:
9546217
34.

Studies of HIV-1 envelope glycoprotein-mediated fusion using a simple fluorescence assay.

Weiss CD, Barnett SW, Cacalano N, Killeen N, Littman DR, White JM.

AIDS. 1996 Mar;10(3):241-6.

PMID:
8882662
35.

NIAID recommendations for treating HIV infection.

Weiss CD.

JAMA. 1994 Jun 15;271(23):1830. No abstract available.

PMID:
7515116
37.
38.

Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Castro BA, Weiss CD, Wiviott LD, Levy JA.

J Clin Microbiol. 1988 Nov;26(11):2371-6.

39.

The human immunodeficiency virus and the adrenal medulla.

Weiss CD.

Ann Intern Med. 1986 Aug;105(2):300. No abstract available.

PMID:
3729215

Supplemental Content

Loading ...
Support Center